Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial (Q33724456)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Edith A Perez

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

4

object named as

George W Sledge

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

2

object named as

Vera J Suman

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

10

object named as

James N Ingle

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

11

object named as

Eric P Winer

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Silvana Martino

7

object named as

Silvana Martino

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Clifford A Hudis

6

object named as

Clifford A Hudis

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

8

object named as

Julie R Gralow

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Nancy E Davidson

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Peter A Kaufman

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Shaker R Dakhil

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Karen A Gelmon

12

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Bernard J Gersh

13

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Allan S Jaffe

14

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Richard J Rodeheffer

15

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

4 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1231-1238

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

21 June 2018

Trastuzumab-associated cardiotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

21 June 2018

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

21 June 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

21 June 2018

Early and delayed clinical cardiotoxicity of doxorubicin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

21 June 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

21 June 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

21 June 2018

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

21 June 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

30 October 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4048960

30 October 2018

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

1 reference

https://pubmed.ncbi.nlm.nih.gov/18250349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/18250349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18250349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://pubmed.ncbi.nlm.nih.gov/18250349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18250349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18250349

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2007.13.5467

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33724456&oldid=2117194823"